{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:42:39Z","timestamp":1792899759841,"version":"4.5.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Oligoprogression is poorly defined in current literature. Little is known about the natural history and significance of oligoprogression in patients with hormone-resistant prostate cancer on abiraterone or enzalutamide treatment [termed androgen receptor-targeted therapy (ARTT)]. The aim of this study was to determine the prevalence of oligoprogression, describe the characteristics of oligoprogression in a cohort of patients from a single center, and identify the number of patients potentially treatable with stereotactic body radiotherapy (SBRT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Castration-resistant prostate cancer (CRPC) patients who radiologically progressed while on ARTT were included. Patients with oligoprogressive disease (OPD) (\u22643 lesions) on any imaging were identified in a retrospective analysis of electronic patient records. Kaplan\u2013Meier method and log-rank test were used to calculate progression-free and overall survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 102 patients with metastatic CRPC on ARTT were included. Thirty (29%) patients presented with oligoprogression (46 lesions in total); 21 (21% of total) patients had lesions suitable for SBRT. The majority of lesions were in the bone (21, 46%) or lymph nodes (15, 33%). Patients with oligoprogression while on ARTT had a significantly better prostate-specific antigen (PSA) response on commencing ARTT as compared to patients who later developed polyprogression. However, PSA doubling time immediately prior to progression did not predict OPD. Median progression-free survival to oligoprogression versus polyprogression was 16.8 vs. 11.7 months. Time to further progression after oligoprogression was 13.6 months in those treated with radiotherapy (RT) for oligoprogression vs. 5.7 months in those treated with the continuation of ARTT alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this study, nearly a third of patients on ARTT for CRPC were found to have OPD. OPD patients had a better PSA response on ART and a longer duration on ARTT before developing OPD as compared to those developing polyprogressive disease (Poly-PD). The majority of patients (70%) with OPD had lesions suitable for SBRT treatment. Prospective randomized control trials are needed to establish if there is a survival benefit of SBRT in oligoprogressive prostate cancer and to determine predictive indicators.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.862995","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T04:28:03Z","timestamp":1652761683000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer\u2014Prevalence and Current Clinical Practice"],"prefix":"10.3389","volume":"12","author":[{"given":"Priyanka H.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Tunariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind A.","family":"Eeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Pathmanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"van As","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison C.","family":"Tree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"B1","unstructured":"Cancer Research UK2020"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-020-00316-x","article-title":"Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A 20-Year Retrospective Analysis in the Largest Healthcare Trust in England","volume":"24","author":"Ng","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in Metastatic Prostate Cancer Without Previous Chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone Plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in Metastatic Prostate Cancer Before Chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased Survival With Enzalutamide in Prostate Cancer After Chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and Increased Survival in Metastatic Prostate Cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2015.05.010","article-title":"Mechanisms of Drug Resistance That Target the Androgen Axis in Castration Resistant Prostate Cancer (CRPC)","volume":"153","author":"Penning","year":"2015","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic Ablative Radiotherapy Versus Standard of Care Palliative Treatment in Patients With Oligometastatic Cancers (SABR-COMET): A Randomised, Phase 2, Open-Label Trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet (London England)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local Consolidative Therapy Versus Maintenance Therapy or Observation for Patients with Oligometastatic Non-Small-Cell Lung Cancer Without Progression After First-Line Systemic Therapy: A Multicentre, Randomised, Controlled, Phase 2 Study","volume":"17","author":"Gomez","year":"2017","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00055","article-title":"Imaging for Metastasis in Prostate Cancer: A Review of the Literature","volume":"10","author":"Turpin","year":"2020","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.02.007","article-title":"SBRT for Oligoprogressive Oncogene Addicted NSCLC","volume":"106","author":"Basler","year":"2017","journal-title":"Lung Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2015.03.006","article-title":"Initial UK Experience of Stereotactic Body Radiotherapy for Extracranial Oligometastases: Can We Change the Therapeutic Paradigm","volume":"27","author":"Aitken","year":"2015","journal-title":"Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70510-7","article-title":"Stereotactic Body Radiotherapy for Oligometastases","volume":"14","author":"Tree","year":"2013","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.eururo.2015.07.004","article-title":"Progression-Free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-Naive Recurrence: A Multi-Institutional Analysis","volume":"69","author":"Ost","year":"2016","journal-title":"Eur Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and Clarification: From the RECIST Committee HHS Public Access","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2016.05.033","article-title":"METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body Magnetic Resonance Imaging-Based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer","volume":"71","author":"Padhani","year":"2017","journal-title":"Eur Urol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.8648","article-title":"End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice","volume":"29","author":"Scher","year":"2011","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.103","article-title":"Efficacy of Stereotactic Body Radiotherapy in Oligorecurrent and in Oligoprogressive Prostate Cancer: New Evidence From a Multicentric Study","volume":"116","author":"Triggiani","year":"2017","journal-title":"Br J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11744","article-title":"Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy","volume":"37","author":"Detti","year":"2017","journal-title":"Anticancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.06.011","article-title":"Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer: Localization of the Progressive Site as a Prognostic Factor","volume":"105","author":"Yoshida","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-021-01424-x","article-title":"Radiotherapy at Oligoprogression for Metastatic Castration-Resistant Prostate Cancer Patients: A Multi-Institutional Analysis","volume":"127","author":"Valeriani","year":"2022","journal-title":"Radiol Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.08.012","article-title":"Progression-Directed Therapy for Oligoprogression in Castration-Refractory Prostate Cancer","volume":"4","author":"Berghen","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ijrobp.2020.07.501","article-title":"Metastasis-Directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-Resistant Prostate Cancer","volume":"4","author":"Deek","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-019-02717-7","article-title":"Metastasis-Directed Stereotactic Radiotherapy for Oligoprogressive Castration-Resistant Prostate Cancer: A Multicenter Study","volume":"37","author":"Triggiani","year":"2019","journal-title":"World J Urol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00352","article-title":"Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer","author":"Salami","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for Prostate Cancer Not Previously Treated With Hormone Therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.862995\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T04:28:06Z","timestamp":1652761686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.862995\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":29,"alternative-id":["10.3389\/fonc.2022.862995"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.862995","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]},"article-number":"862995"}}